Jeito Capital, Ridgeback Capital, SV Health Investors and Fidelity Management & Research led a $156m Series B funding round in Quell Therapeutics. Additional investors include Syncona, British Patient Capital, Janus Henderson, Monashee Investment Management, Point72 and Tekla Capital. “Quell is at the forefront of a new wave of cell therapy. We are leading the way with our highly-differentiated, multi-modular approach to Treg therapy engineering and production. We are proud to have the support of this premiere syndicate of investors as we drive forward to our next stage of growth. With this financing, we have the full suite of capabilities – capital, cutting-edge science, and a world-class team – to advance our pipeline and platform to key milestones on our path ultimately to deliver potentially transformative therapies to patients suffering from diseases caused by immune dysregulation,” Iain McGill, Quell Therapeutics CEO.